Found 629 clinical trials
Fatty Liver
[1] More than 90% of all heavy drinkers develop fatty liver while about 25% develop the more severe alcoholic hepatitis.
- 0 views
- 14 Mar, 2022
- 1 location
The Canadian COVID-19 Prospective Cohort Study (CANCOV)
The CANCOV study will be the first Canadian study to provide a comprehensive evaluation of early and 1-year outcomes of outpatient and hospitalized COVID-19 survivors and their family caregivers, their varied trajectories and associated clinical risk factors. The overall objectives are to determine short- (in hospital) and longer-term (1, 3, …
- 0 views
- 19 Nov, 2021
- 9 locations
Vigor and the LDR in Parkinson Disease Test
Parkinson disease (PD) is a common disorder in which reduced speed of movement results from inadequate brain production of the chemical dopamine. The most effective treatment for PD is the drug levo-dopa, which partially replaces brain dopamine. Despite decades of successful use, how levo-dopa improves speed of movement in PD …
- 0 views
- 13 Nov, 2024
- 2 locations
Impact of Obesity on Periodontal Health in a Sample of Adult Egyptian Patients: A Comparant Study
Periodontal disease is defined as "an inflammatory disease of the tooth supportive structure caused by specific microorganisms or groups of specific microorganisms, resulting in progressive destruction of the periodontal ligament and alveolar bone with increased probing depth formation, recession, or both". According to WHO, overweight and obesity are defined as …
- 0 views
- 10 Jan, 2023
- 1 location
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
This study is an observational, prospective study examining the role point-of-care echocardiography of predicting short term adverse outcomes in emergency department patients with acute pulmonary embolism. The primary objective is to assess the diagnostic performance of ultrasound-guided measures of right ventricular dilation (RVD) and strain in predicting clinical outcomes in …
- 0 views
- 14 Mar, 2022
- 1 location
MicroNet-covered Stent System for Stroke Prevention in All Comer Carotid Revascularization
All-comer study of unselected patients suitable for carotid artery revascularization to evaluate the feasibility, efficacy and safety of first line endovascular revasculariztion using MicroNet covered stent (CGuard) in the treatment of consecutive symptomatic and increased-stroke-risk asymptomatic carotid lesions that require revascularization by Neurovascular Team decision.
- 0 views
- 16 Feb, 2024
- 1 location
A Study Evaluating The Safety Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
The study consists of two parts: [1] Part A: Safety run-in cohort of approximately 12 participants; [2] Part B: Expansion cohort of approximately 38 participants. All participants in this study will continue to be treated until progression of disease, loss of clinical benefit, unacceptable toxicity or withdrawal of consent.
- 0 views
- 16 Feb, 2024
- 18 locations
Evaluation of a Health Promoting Community Center Network (HPCCN) Innovation.
This is a program review of a program which will be planned in a community based participatory level, based on the socioecological model. A pre-post design will be utilized where all community centers in the study will be exposed to the intervention components. It is hypothesized that community centers who …
- 0 views
- 16 Feb, 2024
- 1 location
Early Screening of Autism Spectrum Disorder in General and Pediatric Practices
The second line professionals are note always trained to use diagnostic tools and tend to address all the children to the third line, even when the diagnostic is not complex. The third lign is saturated by all these requests.
- 0 views
- 16 Feb, 2024
- 1 location
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
This is a blinded study, so neither patients nor their doctors will know whether a patient gets tucatinib or placebo. All patients in the study will get T-DM1, a drug that is often used to treat this cancer. Each treatment cycle lasts 21 days.
- 0 views
- 14 Mar, 2022
- 228 locations